News and Events

Paris, France et Camberley, Royaume-Uni – 4 septembre 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, annonce que, à la suite de l’annonce du 27 juillet 2020, le Groupe a lancé un test COVID-19 d’amplification en chaîne par polymérase (PCR) à deux gènes cibles marqué CE. http://novacyt.com/wp-content/uploads/2020/09/Novacyt-Lancement-du-test-COVID-19-à-deux-gènes-cibles-FR.pdf

Paris, France and Camberley, UK – 4 September 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the announcement on 27 July 2020, the Company has launched a CE-Mark approved polymerase chain reaction (PCR) two gene target test for COVID-19. http://novacyt.com/wp-content/uploads/2020/09/Novacyt-launch-of-2-gene-COVID-19-test-ENG.pdf

New test differentiates COVID-19 from common winter diseases Paris, France and Camberley, UK – 27 August 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of its CE-Mark approved polymerase chain reaction (PCR) respiratory test panel, Winterplex™. http://novacyt.com/wp-content/uploads/2020/08/Novacyt-launch-of-respiratory-test-panel-ENGLISH.pdf